AQP4 and neuromyelitis optica: The recommendation of inebilizumab is supported by a single RCT (high-quality evidence): “A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders”12(N-Momentum), a phase-2/3 RCT that enrolled 230 patients, 93% of whom were AQP4-IgG-seropositive.